Published in PLoS One on December 08, 2014
Microbiota-driven transcriptional changes in prefrontal cortex override genetic differences in social behavior. Elife (2016) 1.69
NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting "stemness". Oncotarget (2017) 0.85
Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res (2016) 0.81
Metabolomics: Bridging the Gap between Pharmaceutical Development and Population Health. Metabolites (2016) 0.78
New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology. Mol Cell Oncol (2015) 0.76
Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable. PLoS One (2016) 0.75
USP9X destabilizes pVHL and promotes cell proliferation. Oncotarget (2016) 0.75
Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer. J Cancer (2015) 0.75
Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro. Clin Transl Sci (2016) 0.75
Metabolomic Profiling of the Effects of Melittin on Cisplatin Resistant and Cisplatin Sensitive Ovarian Cancer Cells Using Mass Spectrometry and Biolog Microarray Technology. Metabolites (2016) 0.75
Development of an Optimized Protocol for NMR Metabolomics Studies of Human Colon Cancer Cell Lines and First Insight from Testing of the Protocol Using DNA G-Quadruplex Ligands as Novel Anti-Cancer Drugs. Metabolites (2016) 0.75
Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells. Metabolites (2017) 0.75
Integrated Metabolomics Assessment of Human Dried Blood Spots and Urine Strips. Metabolites (2017) 0.75
Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell (2001) 15.05
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 8.41
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell (2007) 6.47
MetaboAnalyst 2.0--a comprehensive server for metabolomic data analysis. Nucleic Acids Res (2012) 5.68
The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem (2004) 5.37
Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc (2011) 4.13
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res (2003) 4.04
A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc (2012) 3.87
Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene (2007) 3.85
Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol (1994) 3.79
Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem (2005) 2.73
Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab (2008) 2.47
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood (2009) 2.28
Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol (2006) 2.21
Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc (2010) 2.18
Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem (2003) 2.04
Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol (2008) 1.87
Enzymology of NAD+ homeostasis in man. Cell Mol Life Sci (2004) 1.80
Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med (2009) 1.70
Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des (2009) 1.69
NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther (2007) 1.67
Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol (2008) 1.61
The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol (2009) 1.60
NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene (2010) 1.58
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One (2008) 1.48
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs (2007) 1.47
Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom (2010) 1.42
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J Biol Chem (2012) 1.36
Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol (2009) 1.34
A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett (1999) 1.30
Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem (2010) 1.27
Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. Nat Protoc (2011) 1.27
Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer (2002) 1.26
Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J Med Chem (2013) 1.22
Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets (2007) 1.19
Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun (2008) 1.16
Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol Rep (2011) 1.15
Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res (2005) 1.15
Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res (2004) 1.15
A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther (2010) 1.04
Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells. PLoS One (2012) 1.00
Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. J Biol Chem (2013) 1.00
Niacin status, NAD distribution and ADP-ribose metabolism. Curr Pharm Des (2009) 0.96
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618. Neoplasia (2013) 0.94
Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. ChemMedChem (2008) 0.85